Company: MLTX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001821586-25-000018
Chunk: 5

Company: MoonLake Immunotherapeutics
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
 securities350,74257,820Purchase of property and equipment(35)(212)Net cash flow provided by (used in) investing activities144,500(116,547)Cash flow from financing activitiesProceeds from long-term debt, net of issuance costs73,022—Issuance of Class A Ordinary Shares, net of transaction costs—52,540Proceeds from options exercised under ESOP100—Stamp duty on capital injection from MoonLake to MoonLake AG—(1,562)Net cash flow provided by financing activities73,12250,978Effect of movements in exchange rates on cash held1,30329Net change in cash and cash equivalents126,255(108,378)Cash and cash equivalents, beginning of period180,426451,169Cash and cash equivalents, end of period$306,681$342,791Supplementary disclosure of cash flow information:Cash paid for interest$(1,156)$—Non-cash operating lease right-of-use assets obtained in exchange for lease obligations$—$370

The accompanying Notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

6

MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2025(Unaudited)

s

Note 1 — Overview of the Company

Corporate InformationMoonLake Immunotherapeutics is a clinical stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases. MoonLake Immunotherapeutics is currently a single asset company focused on the development of Sonelokimab (“SLK”), a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.

Unless the context otherwise requires, “MoonLake” and the “Company” refer to the combined company following the Business Combination (as defined in Note 2 — Business Combination Agreement with Helix and Recapitalization included in MoonLake’s audited consolidated financial statements and notes thereto for the year ended December 31, 2024 included in MoonLake’s Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission (“SEC”) on February 26, 2025 (the “Annual Report”)) consummated on April 5, 2022, together with its subsidiaries.